Table S5 from Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
posted on 2023-03-31, 20:47authored byElena Bonazzoli, Federica Predolini, Emiliano Cocco, Stefania Bellone, Gary Altwerger, Gulden Menderes, Luca Zammataro, Anna Bianchi, Francesca Pettinella, Francesco Riccio, Chanhee Han, Ghanshyam Yadav, Salvatore Lopez, Aranzazu Manzano, Paola Manara, Natalia Buza, Pei Hui, Serena Wong, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Gloria S. Huang, Masoud Azodi, Peter E. Schwartz, Joseph Schlessinger, Alessandro D. Santin
Average quantitative nuclear histological score associated with the ex vivo c-Myc expression assessed by IHC in the ARK2 xenograft tumor samples, excised 1 hour, 6 hours and 12 hours after the last dose of GS-5829 at 20, 10 mg/kg, JQ1 at 50 mg/kg and vehicle for oral gavage studies, following 28 days of treatment.
Funding
NIH
the Deborah Bunn Alley Foundation, the Tina Brozman Foundation, the Discovery to Cure Foundation and the Guido Berlucchi Foundation to